SCHEMBL1908441

SCHEMBL1908441

COc1cc(-c2cnn(C)c2)cn2ncc(C(=O)NCCc3ccncc3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 1/20 0.46
CNR2 P34972 4/20 0.44
TLR9 Q9NR96 1/20 0.44
TLR7 Q9NYK1 1/20 0.44
HCRTR2 O43614 1/20 0.42
ROCK2 O75116 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
ROCK1 Q13464 1/20 0.42
GSK3B P49841 2/20 0.41
WNT1 P04628 1/20 0.41
DYRK1A Q13627 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CDK2 P24941 1/20 0.41
MAPK1 P28482 1/20 0.41
RET P07949 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1906405 0.91 HCRTR2 (0.49) HCRTR2CYP3A4MAPK1RET
SCHEMBL1906358 0.85 ALDH1A1 (0.47) ALDH1A1KDM4EHCRTR2RET
SCHEMBL1905270 0.84 IKBKE (0.57) ALDH1A1GSK3BWNT1DYRK1ASMN1; SMN2
SCHEMBL2351725 0.83 MAPK1 (0.44) ALDH1A1KDM4EHCRTR2ROCK2ROCK1
SCHEMBL1902267 0.83 RECQL (0.58) ALDH1A1KDM4EHCRTR2ROCK2CYP3A4
SCHEMBL1899521 0.82 MKNK1 (0.42) ALDH1A1KDM4EGSK3BWNT1DYRK1A
SCHEMBL2352817 0.81 IGF1R (0.44) TLR9TLR7HCRTR2RETUSP30
SCHEMBL1908129 0.80 TTK (0.46) HCRTR2RETUSP30
SCHEMBL1906769 0.80 HTR4 (0.43) CNR2HCRTR2GSK3BDYRK1ACDK2
SCHEMBL1907765 0.79 PDE10A (0.49) ALDH1A1KDM4ETLR9TLR7HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US claimed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US claimed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 ALDH1A1 4287/4885KDM4E 1778/4885CNR2 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.